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Bleomycin is a highly effective antitumor agent, but pulmonary toxicity, characterized by an acute
inflammatory reaction and associated pulmonary edema, limits clinical use of the drug. Platelets and
platelet-activating factor (PAF), a membrane-derived phospholipid, have been implicated in the
mechanisms that can mediate pulmonary microvascular injury. We sought to investigate the role ofPAF
in bleomycin-induced lung injury in the rat, using the PAF receptor antagonist BN 52021; and the role
of platelets though the use of an anti-platelet antibody. Lung injury was induced by intratracheal
bleomycin (1.5 mg) and assessed by measurements oflungwet weight and total pulmonary extravascular
albumin space (TPEAS). Bleomycin caused a significant increase in both indices after 48 hr, compared
with control animals (p < 0.05). A single dose ofBN 52021 (20 mg/kg orally) significantly reduced the
bleomycin-induced increase in lung weight, but not the rise in TPEAS (p > 0.05). Increasing the dose
of BN 52021 (20 mg/kg/12 hr, orally) had no additional effect. Reducing circulating platelet numbers
by approximately 75% had no effect on either the increase in lung weight or TPEAS, observed 48 hr
after bleomycin (p > 0.05). PAFmay partially contribute to the acute infiamtory reaction seen after
intratracheal bleomycin in rats.
Introduction
Bleomycin, an antibiotic derived from Streptomyces
vertillus, is a highly effective antitumor agent that is
widely used in the treatment oflymphomaand testicular
and squamous cell tumors (1). Pulmonary toxicity is a
prominent side effect of the drug, limiting the dose that
may be used in clinical practice. In severely affected
patients, a pneumonitis may develop similar to that of
the adult respiratory distress syndrome (ARDS),
characterized by increased vascular permeability,
pulmonary edema, and refractory hypoxemia with a high
associated mortality (2-4). Although several conditions
predispose the lung to injury-including doses of
bleomycin in excess of450 mg, concomitant exposure to
radiation, combination therapy with other agents, and
impaired renal function-the mechanisms underlying
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the pulmonary toxicity remain unknown (5). Similarities
in pathology and clinical presentation between
bleomycin-induced lung injury and ARDS suggest a com-
mon etiology (5,6).
Bleomycin administered intratracheally in rats has
been shown, in our laboratory and those of others, to pro-
duce histological changes similar to those seen in ARDS
(6). These comprise an early inflammatory phase
characterized by neutrophil influx and increased
microvascular permeability, maximal after 72 hr (7), and
followed by fibrosis that is maximal at 2 to 3 weeks (8).
Many previous investigators have focused on the role of
vasoactive substances and inflammatory cells in
generating acute edematous lung injury (9,10). Platelet-
activating factor (PAF) is a membrane-derived
phospholipid that has been shown to mediate both the
pulmonary microvascular injury and acute inflammatory
changes that follow administering endotoxin to rats (11).
In a previous study, we have also shown PAF to be a
potent mediator of increased vascular permeability in
the bronchial circulation ofthe guinea pig, an effect that
can be abolished using a PAF-receptor antagonist, the
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ginkgolide mixture BN 52063 (12). The sequestration of
platelets in the lungs of patients with ARDS, together
with experimental evidence to suggest that platelets
may directly damage alveolar capillary membranes and
intereact with neutrophils to produce inflammatory
mediators, has also led to speculation regarding their
potential role in the generation of acute lung injury (10).
In the current study, we therefore investigated the ef-
fects of the ginkgolide PAF-receptor antagonist BN
52021, which is the active component of BN 52063, and
of platelet depletion on the acute (inflammatory) phase
of bleomycin-induced lung injury in the rat.
Methods
Male Lewis rats (175-225 g, Charles River, UK) were
anesthetized with intramuscular Hypnorm (fentanyl
citrate 0.315 mg/mL and fluanisone 10 mg/mL) at a dose
of0.5 to 1.0 mL/kgbody weight, prior to each procedure.
Intratracheal Bleomycin
Animals received 1.5 mg of bleomycin in 0.3 mL of
0.9% saline by intratracheal instillation. Control animals
received 0.3 mL of saline alone. Animals were sacrific-
ed 48 hr after receiving bleomycin.
Administration of BN 52021
BN 52021, 20 mg/kg in 0.5% carboxymethyl cellulose
(20 mg/mL), was administered by gavage at varying time
intervals. Control animals received 0.5% carboxymethyl
cellulose alone (1 mL/kg).
Assessment of Tbtal Pulmonary
Extravascular Albumin Space
Total pulmonary extravascular albumin space (TPEAS)
was measured using a method modified from that of
Wangensteen et al. (13) and described in full elsewhere
(6). Twenty-four hours before being sacrificed, each
animal received 1 to 2 IACi of 125I-labeled human serum
albumin (Amersham International Ltd., UK) IV via a tail
vein, in a total volume of 0.5 mL of 0.9% saline. The
animals were anesthetized and exsanguinated via the
aorta 24 hr later. The pulmonary circulation was flush-
ed free of blood by ligating a cannula within the right
ventricle and perfusing with 12 mL of phosphate-
buffered saline. The lungs were removed and dissected
free of the main bronchi and blood vessels. They were
gently blotted to remove excess surface fluid, weighed,
and placed in a counting vial. Duplicates of 0.1 mL
plasma were also counted in a gamma counter. Total
pulmonary extravascular albumin space was calculated
as the ratio of total lung radioactivity to that of 1 mL
plasma.
Experimental Protocols
The effect ofBN 52021 on bleomycin-induced lung in-
jury was first assessed by administering a single dose of
drug (n = 7) or the vehicle alone (n = 8) to rats 30 min
prior to receiving bleomycin. A third control group
received intratracheal saline (n = 5). All animals were
sacrificed 48 hr later.
To test for a possible dose-dependent effect of BN
52021, in a second experiment animals received BN
52021 (n = 9) or the vehicle alone (n = 6) 30 min prior
to the bleomycin and subsequently at 12-hr intervals up
to 48 hr, when they were sacrificed. A third, control
group received intratracheal saline (n = 3).
Tb assess the possible role of platelets in bleomycin-
induced lung injury, in a third experiment animals re-
ceived either 1.0 mL/kg rabbit serum by IP iWection (n
= 6), or 1.0 mL/kg ofthe rabbit anti-rat platelet antibody
(IP, n = 6)24 hr prior to the bleomycin. Fullblood counts
were measured 24 hr later, and the animal were sacri-
ficed (as before) 48 hr after receiving the bleomycin.
Drugs and Chemicals
Drugs and chemicals were obtained from the follow-
ing sources: Hypnorm from Janssen Pharmaceuticals
(Oxford, UK); bleomycin from Lundbeck Pharmaceuti-
cals (UK); BN 52021 was a kind gift from Dr. P. Braquet
(Laboratories Henri Beaufour, Paris, France); and anti-
platelet antibody a kind gift from Dr. K. Butler (Ciba
Laboratories, West Sussex, UK).
Statistical Methods
Comparisons between groups were made using the
Mann-Whitney U test. Values less than 0.05 were con-
sidered significant.
Results
Wet weight and TPEAS for animals in experiment 1
are shown in Figure 1. Administration ofbleomycin caus-
ed a significant increase in lung weight and TPEAS in
both groups of animals, compared with controls (p <
0.05). Administration of the PAF receptor antagonist BN
52021 caused a significant reduction in the increase in
lung weight compared with vehicle (1.09 ± 0.10, mean
± SEM, vs. 1.64 ± 0.19 g, p < 0.05). The increase in
TPEAS was attenuated by BN 52021, although this did
not achieve statistical significance (0.31 ± 0.05 vs. 0.41
± 0.05, p < 0.05).
Data from the second study, in which animals were
given multiple doses ofBN 52021, are shown in Figure 2.
The increase in lungwet weight caused by bleomycin was
significantly altered by BN 52021 (1.17 + 0.04 vs. 1.33
+ 0.05, p < 0.05). The bleomycin-induced increase in
TPEAS was reduced with BN 52021, but, again, not
significantly so (0.57 ± 0.01 vs. 0.41 ± 0.02, p = 0.07).
The results for the third study are shown in Figure 3.
Platelets were significantly (p < 0.05) reduced in
the antibody-treated group, compared with serum
(mean count 252 x 109/L vs. 947 x 109/b). Neither
hemoglobin nor white cell count were significantly
altered. There was no significant difference between
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FIGURE 1. Changes in lung weight and total pulmonary
extravascularalbumin space (TPEAS) in rats treated with BN 52021
20 mg/kg or 0.5% carboxymethyl cellulose (vehicle) orally 30 min
prior to receiving intratracheal bleomycin 1.5 mg or saline
(control) and perfused 48 hr later. Horizontal bars indicate mean
values, Dagger (t) indicates significant increase compared with con-
trol. Asterisk (*) indicates significant decrease compared with
bleomycin plus vehicle.
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FIGURE 3. Changes in lung weight and TPEAS in animals treated
with anti-platelet antibody or serum, 12 hr before treatment with
BN 52021 20 mg/kg or0.5% carboxymethyl cellulose (vehicle). In-
tratracheal bleomycin 1.5 mg was administered 30 min later.
Horizontal bars indicate mean values.
the groups for either lung weight (1.10 + 0.03 for vehicle
vs. 1.19 ± 0.09 g for BN 52021 animals) or TPEAS
(0.46 ± 0.06 vs. 0.40 ± 0.06).
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FIGURE 2. Changes in lung weight and total pulmonary extravascu-
lar albumin space (TPEAS) in rats treated with BN 52021 20 mg/kg
or 0.5% carboxymethyl cellulose (vehicle) 30 min prior to in-
tratracheal bleomycin 1.5 mgor saline (control) and at 12-hr inter-
vals thereafter, and perfused after 48 hr. Horizontal bars indicate
mean values. Dagger (t) indicates significant increase compared
with control. Asterisk (*) indicates significant decrease compared
with bleomycin plus vehicle.
Discussion
Any therapeutic intervention that might be developed
by an understanding of the mechanisms underlying
bleomycin-induced lung injury would considerably
extend the clinical effectiveness of the drug. Our results
suggest that PAF may be partially responsible for the
acute inflammatory response seen after intratracheal ad-
ministration of bleomycin in the rat, although only one
of the measured indices, the lung weight, was affected
by administration of the drug.
In previous studies changes in lung weight have been
shown to correlate well with acute lung injury and subse-
quent fibrosis (14). Further attenuation of the effects of
bleomycin was not achieved by increasing the dose of
BN 52021. We previously showed that a smaller dose of
a less potent, but related PAF receptor antagonist, BN
52063, is completely effective in abolishing the inflam-
matory effects of exogenously administered PAF, as in-
dicated by changes in microvascular permeability in the
bronchial circulation ofthe guineapig(12). Interestingly,
although increasing the total dose of BN 52021 ad-
ministered in the second experiment did not further at-
tenuate the increase in lungweight seen after bleomycin,
the reduction in TPEAS almost achieved statistical
significance (p = 0.07).
WEIGHT (G)
2.0 1
1.8
1.6
1.41
1.2
1.0
0.8
O0
1.8
1.6
1.4
1.2 l
1.0
0.8
67
OT
68 EVANS ETAL.
Wagensteen et al. (13) have shown that intratracheal
bleomycin in the rat does not increase lung wet/dry
weight ratio, suggesting that the increase in lung weight
could be the result of inflammatory cell influx into the
lungs. Previous work from our laboratory showed signifi-
cant increases in the recovery ofinflammatory cells such
as neutrophils, lymphocytes, and monocytes in broncho-
alveolar lavage fluid from rats that were treated with
bleomycin (6). It is possible that the PAF antagonist BN
52021 inhibits the chemotaxis of neutrophils into the
lungs since PAF possesses chemotactic effects for
neutrophils in vitro (15).
Our measurement of albumin space, TPEAS, is not
necessarily an index of vascular permeability to albumin
as shown by Wagensteen et al. (13). Indeed, by using a
new method for specifically assessing albumin
permeability they found only a small significant increase
after dosing with bleomycin, but TPEAS was approx-
imately doubled, as we observed in our present study.
It is possible that the increase in TPEAS is a reflection
of a direct effect of bleomycin on the lung interstitial
space that allows albumin to occupy more of the inter-
stitial volume. Presumably, neither PAF nor platelets
would effect this process. Thus, the two indices of lung
injury we measured may reflect different pathological
processes induced by bleomycin.
Despite the failure ofBN 52021 to prevent pulmonary
injury in the rat model, PAF may still be a partial
mediator ofbleomycin-induced lung injury in man. PAF
is one of the most potent inflammatory mediators known
to increase microvascular leakage in different vascular
beds in several animal species, and it has many of the
properties that can induce the pathophysiologic
responses of acute lung injury. Pulmonary endothelial
damage has been observed following the administration
of PAF in several animal models, and it is indicated by
increasing lymph flow, elevated lymphatic albumin and
globulin content, and increased lung weight (16).
The IV administration of PAF has been shown to alter
lung mechanics in rabbits and guinea pigs in a similar
manner to that seen clinically in patients with bleomycin-
induced pulmonary inijury andARDS (17,18). Endothelial
damage accompanied by platelet and leukocyte plugs
are also observed in the pulmonary capillaries of experi-
mental animals after PAF administration (19). However,
the release of PAF during induction of acute lung injury
in experimental animals has yet to be demonstrated,
possibly because of its short plasma half-life (20). The
biological effect ofPAFmay be amplified by the presence
of other mediators released from activated neutrophils
and platelets. Such mediators include lysosomal en-
zymes, toxic oxygen radicals, thromboxane, and leuko-
trienes (21,22). It may be that a combination of antago-
nists to a variety ofmediators may be required to achieve
the further blockade of acute lung injury in thisand other
models. For example, in a previous study, we were able
to only partially inhibit endotoxin-induced increases in
airway microvascular permeability in guinea pigs using
PAF receptor antagonists alone, suggesting that addi-
tional factors were involved (23).
Evidence suggests that platelets are a critical compo-
nent in the generation of acute lung irjury (10). In some
species, the release of vasoactive inflammatory
mediators is, at least, partially dependent upon the
presence of platelets (24), which together with neutro-
phils release inflammatory mediators when activated by
endothelial-derived mediators such as PAF and throm-
boxane. Aggregation of platelets and neutrophils in the
lungs of experimental animals has been observed in
models of acute lung injury (21).
We were unable to show that a reduction in platelet
count caused any significant reduction in bleomycin-
induced lung injury. This may have been due to an inade-
quate reduction in platelet numbers (approximately 75'%
inhibition), although the maximal effect of the antibody
occurs 12 hr after administration, and the platelet counts
(measured at 24 hr) may therefore not have reflected the
period of maximum suppression.
The results of the present study suggest that PAF may
be partly involved in mediating bleomycin-induced acute
lung injury in the rat, perhaps by inhibiting the inflam-
matory cell recruitment. Nevertheless, it is increasingly
clear from this and other investigations that no single
pathway leads directly towards acute edematous lung
injury. It is more likely that a large number of humoral
factors, inflammatory cells, and mediators interact with
other currently undefined agents to promote vascular
endothelial cell damage and respiratory failure. Conse-
quently, although further studies using newly available
antagonists with greater potency (25) are indicated,
these should possibly be carried out in combination with
depletion of inflammatory cells.
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